- Home
- OPEN vs ARQT Comparison
OPEN vs ARQT Comparison
Compare OPEN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPEN
- ARQT
- Stock Information
- Founded
- OPEN 2014
- ARQT 2016
- Country
- OPEN United States
- ARQT United States
- Employees
- OPEN N/A
- ARQT N/A
- Industry
- OPEN Real Estate
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- OPEN Finance
- ARQT Health Care
- Exchange
- OPEN Nasdaq
- ARQT Nasdaq
- Market Cap
- OPEN N/A
- ARQT 1.7B
- IPO Year
- OPEN N/A
- ARQT 2020
- Fundamental
- Price
- OPEN $1.04
- ARQT $15.25
- Analyst Decision
- OPEN Hold
- ARQT Strong Buy
- Analyst Count
- OPEN 5
- ARQT 6
- Target Price
- OPEN $1.70
- ARQT $18.80
- AVG Volume (30 Days)
- OPEN 102.4M
- ARQT 1.9M
- Earning Date
- OPEN 08-05-2025
- ARQT 08-13-2025
- Dividend Yield
- OPEN N/A
- ARQT N/A
- EPS Growth
- OPEN N/A
- ARQT N/A
- EPS
- OPEN N/A
- ARQT N/A
- Revenue
- OPEN $5,125,000,000.00
- ARQT $212,819,000.00
- Revenue This Year
- OPEN N/A
- ARQT $61.01
- Revenue Next Year
- OPEN $22.65
- ARQT $37.95
- P/E Ratio
- OPEN N/A
- ARQT N/A
- Revenue Growth
- OPEN 2.36
- ARQT 100.03
- 52 Week Low
- OPEN $0.51
- ARQT $7.86
- 52 Week High
- OPEN $3.09
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- OPEN 73.92
- ARQT 65.06
- Support Level
- OPEN $0.73
- ARQT $13.06
- Resistance Level
- OPEN $0.60
- ARQT $15.36
- Average True Range (ATR)
- OPEN 0.09
- ARQT 0.65
- MACD
- OPEN 0.05
- ARQT 0.22
- Stochastic Oscillator
- OPEN 88.37
- ARQT 91.54
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.